Back HCV Treatment

HCV Treatment

EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir

Almost all children age 6 to 11 with hepatitis C who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver damage even at that young age, according to a presentation at the at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C

AbbVie's pangenotypic direct-acting antiviral combination of 2 drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV) infection, the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

EASL 2017: International Liver Congress Starts This Week in Amsterdam

The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at aidsmap.com will be providing on-site coverage of meeting highlights.

alt

Read more:

Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.

HIVandHepatitis.com coverage by topic

CROI website

4/16/17

alt

FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C

The U.S. Food and Drug Administration (FDA) on April 7 approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents age 12 to 17 years. Sofosbuvir/ledipasvir (Harvoni) is now indicated for adolescents with HCV genotypes 1, 4, 5, or 6, while sofosbuvir (Sovaldi) plus ribavirin is approved for those with genotypes 2 or 3.

alt

Read more: